Manuel Haeckl

Manuel Haeckl currently serves as the Global Medical Director Oncology at Basilea Pharmaceutica, where he plays a pivotal role in shaping the company's strategic approach to innovative cancer therapies. His extensive background as a Medical Doctor and Biochemist, combined with over a decade of experience in Medical Affairs, uniquely positions him to lead complex clinical development initiatives within a highly dynamic and multidisciplinary environment. At Basilea, Manuel is responsible for overseeing the medical strategy for Phase 1b/2 clinical studies in solid tumors, including lung cancer and dermatologic oncology, ensuring the integration of scientific rigor with regulatory and commercial considerations. His expertise in designing and implementing clinical study protocols, along with his proficiency in medical monitoring and safety data review, enables him to effectively support study teams and optimize clinical trial outcomes.

A key aspect of Manuel’s role involves participating in the development of clinical development plans and strategies that align with the latest advancements in cancer immunotherapy and precision medicine. His skills in data analysis and clinical development are instrumental in interpreting complex safety and efficacy data, which informs decision-making and publication planning. Additionally, Manuel actively contributes to the planning and management of clinical study reports and scientific publications, fostering transparent scientific communication. His deep understanding of medical education, compassionate use programs, and strategic management further enhances his ability to lead cross-functional teams and advance Basilea’s pipeline. With a passion for scientific excellence and patient-centric innovation, Manuel Haeckl continues to drive impactful medical strategies that aim to improve outcomes for patients battling cancer.